In a phase 3 trial for patients with advanced melanoma, combination of IL-2 with short gp100 (209–217) peptide emulsified in IFA resulted in a modest but significant improvement of overall clinical responses, progression-free survival and overall survival, compared to IL-2 treatment alone [89]. This evidence concerns the gene IL2 and melanoma.